Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
09/2003
09/12/2003CA2477119A1 Compounds that modulate the activity of ptp-1b and tc-ptp
09/12/2003CA2477075A1 Pharmaceutical and cosmetic compositions comprising plgf-1
09/12/2003CA2476757A1 Nitrogen-containing heterocyclic compound
09/12/2003CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/11/2003WO2003074500A2 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
09/11/2003WO2003074075A1 Pharmaceutical and cosmetic compositions comprising plgf-1
09/11/2003WO2003074056A1 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
09/11/2003WO2003074054A1 Ophthalmic composition comprising ascomycin
09/11/2003WO2003074046A1 Antidepressant
09/11/2003WO2003074024A1 Formoterol superfine formulation
09/11/2003WO2003073995A2 Dna vaccine against proliferating endothelial cells and methods of use thereof.
09/11/2003US20030172389 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
09/11/2003US20030171564 Novel argS
09/11/2003US20030171552 A single-chain T-cell receptor covalently linked to single-chain antibody; anticarcinogenic agents for treating cancer
09/11/2003US20030171547 Adipocyte-specific protein homologs
09/11/2003US20030171541 Selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides; diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides
09/11/2003US20030171537 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
09/11/2003US20030171438 Method for treatment of external secretion disorders
09/11/2003US20030171429 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues
09/11/2003US20030171422 Aldose reductase inhibitors; antidiabetic agents
09/11/2003US20030171420 Using a thiolactomycin compound as parasiticide
09/11/2003US20030171419 Pharmaceutical compositions comprising fluvastatin
09/11/2003US20030171418 Pyranoindazoles and their use for the treatment of glaucoma
09/11/2003US20030171416 Nordihydroguaiaretic acid; anticancer agents, viricides
09/11/2003US20030171415 Strokes; cardiovascular disorders; mixture of melmisartan and ramipril
09/11/2003US20030171414 Valsartan; hypotensive agents, cardiovascular disorders, anticholesterol agents, antilipemic agents
09/11/2003US20030171411 Amide derivatives as therapeutic agents
09/11/2003US20030171404 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
09/11/2003US20030171400 Rheumatic diseases; osteoporosis; multiple sclerosis; autoimmune disease; joint replacements
09/11/2003US20030171396 Sulfonamide compounds and uses thereof as medicines
09/11/2003US20030171393 Drugs for sex dysfunctions
09/11/2003US20030171392 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
09/11/2003US20030171389 Anticancer agents; bone disorders; antiarthritic agents
09/11/2003US20030171386 Small molecules for the treatment of abnormal cell growth
09/11/2003US20030171383 Administering adenosine A2 receptor antagonist
09/11/2003US20030171381 Therapy for Parkinson's disease; antidepressants; antiepileptic agents
09/11/2003US20030171378 Indolinone derivatives
09/11/2003US20030171365 Inhibitors of the interleukin-1beta conversion enzyme; useful in treatment of inflammatory, auto-immune and neurodegenerative diseases
09/11/2003US20030171362 Amino-tetralin derivatives as muscarinic receptor antagonists
09/11/2003US20030171361 Treatment of impotence, sexual dysfunction in female, stable, unstable and variant angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis
09/11/2003US20030171359 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases
09/11/2003US20030171358 New compounds, their preparation and use
09/11/2003US20030171357 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
09/11/2003US20030171356 Methods for alzheimer's disease treatment and cognitive enhancement
09/11/2003US20030171353 Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
09/11/2003US20030171352 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
09/11/2003US20030171342 Novel 16-ene-C25-oxime and 16-ene- C-25-oxime ether analogs of 1 alpha ,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24.
09/11/2003US20030171337 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and
09/11/2003US20030171324 Reagents which bind to human DESC1-like serine protease gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to cancer, chronic obstructive pulmonary disease (COPD),
09/11/2003US20030171320 Methods for treating ocular neovascular diseases
09/11/2003US20030171314 Early protection of susceptible animals against foot and mouth disease (FMD) may be achieved by inoculating the animals with a vaccine comprising an interferon DNA sequence. One day after inoculation, animals have been found protected from
09/11/2003US20030171305 Tetraphenylbacteriochlorin derivatives and compositions containing the same
09/11/2003US20030171302 Opioid derivative
09/11/2003US20030171294 Unit angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF, Inducing angiogenesis or myocardial perfusion or vascular density into a heart
09/11/2003US20030171288 Methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of
09/11/2003US20030171282 Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment
09/11/2003US20030171278 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the
09/11/2003US20030171269 Novel epidermal growth factor protein and gene, and methods of use therefor
09/11/2003US20030171267 Albumin fusion proteins
09/11/2003US20030171266 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
09/11/2003US20030171255 Modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1),
09/11/2003US20030170839 Type 2 cytokine receptor and nucleic acids encoding same
09/11/2003US20030170808 Polypeptide encoded by polynucleotide of given sequence; use in diagnosis and treatment of various diseases
09/11/2003US20030170785 CDNA encoding the human alpha2 delta4 calcium channel subunit
09/11/2003US20030170746 Method for screening an agent for ability to inhibit heparanase activity
09/11/2003US20030170730 Testing for drug desistance of cancer drugs
09/11/2003US20030170727 Drug screening; cental nervous system disorders
09/11/2003US20030170679 Hybrid growth hormone
09/11/2003US20030170662 Screening bactericides, herbicides, malaria drugs using enzymes
09/11/2003US20030170628 Forsenic analysis; medical diagnosis; chromosome markers
09/11/2003US20030170331 Plant extract of the olea europaea as no-synthase inhibitor and uses
09/11/2003US20030170329 Cytokine production inhibitors, agents for protecting and promoting liver funtion, anti-inflammatory agents, immunosuppressants, drugs, cosmetics, foods and food materials
09/11/2003US20030170320 Extract is composed of carboxy alkyl esters, especially quinic acid lactone.
09/11/2003US20030170319 Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
09/11/2003US20030170315 Bioactivation of iron salt, especially an ferric ferrous salt, by adding a magnesium salt (MgCl2); useful as a medicine to treat diseases such as diabetes, freshness preservative agent, and animal and plant growth promoter
09/11/2003US20030170309 Pharmaceutical compositions containing polymer and drug assemblies
09/11/2003US20030170304 Delivers an active ingredient in a pulsed or bimodal manner.
09/11/2003US20030170300 Combination chemotherapy
09/11/2003US20030170297 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
09/11/2003US20030170287 Rapamycin or a rapamycin derivative having mTOR inhibiting properties
09/11/2003US20030170286 Codrug with at least two constituent moieties cleavably linked covalently to one another; dimensioned to position two radiation seeds a predetermined distance apart.
09/11/2003US20030170275 Such as pain, mental disorders such as schizophrenia and stress-related disorders such as depression using, especially, M. vaccae material.
09/11/2003US20030170274 Activation of HCV-specific T cells
09/11/2003US20030170270 Nucleic acid encoding an infectious, nonpathogenic PCV1, which contains an immunogenic open reading frame gene of a pathogenic PCV2 in place of an ORF gene of the PCV1 nucleic acid molecule.
09/11/2003US20030170265 Use of grifola frondosa fungus extracts
09/11/2003US20030170253 Useful in stimulating angiogenesis as well as in diagnostic applications.
09/11/2003US20030170242 Novel isoforms of vascular endothelial cell growth inhibitor
09/11/2003US20030170234 Combination of the antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin; treating cancer
09/11/2003US20030170231 Remedies and preventives for antiphospholipid antibody syndrome
09/11/2003US20030170217 Bifidobacterium in the treatment of inflammatory disease
09/11/2003US20030170216 SYN3 compositions and methods
09/11/2003US20030170208 To promote osteogenesis and therefore uses include fracture healing and repair and acceleration of fracture healing
09/11/2003US20030170174 For therapy of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation; contrast agents
09/11/2003US20030167999 Crystal
09/10/2003EP1343013A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents.
09/10/2003EP1342795A2 Method of detecting a variant of gh1 as indicator of growth hormone dysfunction
09/10/2003EP1342728A1 Radiosensitivity enhancers in radiotherapy for cancer and nucleic acids and proteins enhancing radiosensitivity
09/10/2003EP1342723A1 Indole derivatives and use thereof in medicines
09/10/2003EP1342721A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin
09/10/2003EP1342717A1 Benzimidazole derivatives
1 ... 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 ... 1564